6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2004
Novogen Limited
(Translation of registrant's name into English)
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
82- ________________ .1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 25 April, 2004 By Ronald Lea Erratt Company Secretary

ASX MEDIA RELEASE
26 APRIL 2004

NOVOGEN WINS $10 MILLION AUSTRALIAN GOVERNMENT FUNDING
FOR PHARMACEUTICAL DEVELOPMENT

The Australian Government's Department of Industry has
approved ASX listed pharmaceutical company Novogen Limited's
application for $10 million research and development (R&D)
funding under its Pharmaceutical Partnerships Program
(P3 Scheme).

Under the terms of this arrangement Novogen stands
to receive the maximum allowable grant of $10 million
over five years, dependent on agreed R&D spending targets.

The scheme is open to all Australian and international
companies engaged in R&D activities in Australia, but
only 11 have been chosen for funding in the present
round of awards.

Novogen is one of only five successful applicants to
have been awarded a grant at the maximum level.
Other top tier recipients include Merck Sharpe & Dohme,
Eli Lilly and CSL.

The Australian Minister for Industry, Mr Ian Macfarlane,
said the successful applicants were drawn from across
the pharmaceutical industry and included biotechnology
companies, a generic medicine manufacturer and
multi-national pharmaceutical companies.

"This is a national pharmaceutical industry policy which
covers the whole value chain so that we capitalise on our
local research," Minister Macfarlane said.

Novogen's funding will be used to accelerate the
development of its lead anti-cancer compound,
phenoxodiol, through Phase II clinical trials.

Phenoxodiol is targeting the treatment of late stage
chemo-resistant tumours and early stage chemo-insensitive
tumours.

In addition, the funding will contribute to Novogen's
expenditure on clinical trials of its lead cardiovascular
and anti-inflammatory compounds, as well as pre-clinical
testing of further compounds which continue to emerge
from its pharmaceutical R&D pipeline.

This will involve biological screening, with possible
entry of promising drug candidates into second stage
screening and/or human clinical trials in due course.

According to Novogen's Managing Director, Mr Christopher
Naughton, the funding offer has come at a strategically
significant time for the Company.

"Independent scientific investigators from the Yale
Medical School recently made public very promising
results from early Phase II trials of phenoxodiol
and we are planning clinical trials of both our
cardiovascular and anti-inflammatory compounds,"
Mr Naughton said.

"These planned activities will impose demands on cash
resources and the Government contribution of this
magnitude will ensure we can implement our pharmaceutical
development strategies in a timely manner".

"Apart from the opportunity this provides to expedite
our R&D plans, the decision reflects an endorsement
by expert advisory panels that our R&D strategies
are both commercially and scientifically sound,"
Mr Naughton said.

Novogen is developing a range of therapeutics across
the fields of oncology, cardiovascular disease and
inflammatory diseases based on its phenolic drug
technology platform. Phenoxodiol is under clinical
development by its subsidiary Marshall Edwards, Inc.,
which has licensed rights to bring phenoxodiol
to market globally.


More information on phenoxodiol and on the
Novogen group of companies can be found at
www.marshalledwardsinc.com and www.novogen.com.

Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995. You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Marshall Edwards, Inc., + 61.2.9878 0088